Taiho Pharmaceutical Co., Ltd. - Product Pipeline Review - H2 2011
Summary
Global Market Direct’s pharmaceuticals report, “Taiho Pharmaceutical Co., Ltd. - Product Pipeline Review - H2 2011” provides data on the Taiho Pharmaceutical Co., Ltd.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Taiho Pharmaceutical Co., Ltd.’s corporate website, SEC filings, investor presentations and featured press releases, both from Taiho Pharmaceutical Co., Ltd. and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
Reasons to buy
Summary
Global Market Direct’s pharmaceuticals report, “Taiho Pharmaceutical Co., Ltd. - Product Pipeline Review - H2 2011” provides data on the Taiho Pharmaceutical Co., Ltd.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Taiho Pharmaceutical Co., Ltd.’s corporate website, SEC filings, investor presentations and featured press releases, both from Taiho Pharmaceutical Co., Ltd. and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
- Taiho Pharmaceutical Co., Ltd. - Brief Taiho Pharmaceutical Co., Ltd. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Taiho Pharmaceutical Co., Ltd. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Taiho Pharmaceutical Co., Ltd. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Taiho Pharmaceutical Co., Ltd.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate Taiho Pharmaceutical Co., Ltd.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Taiho Pharmaceutical Co., Ltd. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Taiho Pharmaceutical Co., Ltd.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Taiho Pharmaceutical Co., Ltd..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Taiho Pharmaceutical Co., Ltd. and identify potential opportunities in those areas.
Taiho Pharmaceutical Co., Ltd. Snapshot
Taiho Pharmaceutical Co., Ltd. Overview
Key Information
Key Facts
Taiho Pharmaceutical Co., Ltd. – Research and Development Overview
Key Therapeutic Areas
Taiho Pharmaceutical Co., Ltd. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Taiho Pharmaceutical Co., Ltd. – Pipeline Products Glance
Taiho Pharmaceutical Co., Ltd. – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Taiho Pharmaceutical Co., Ltd. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Taiho Pharmaceutical Co., Ltd. – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Taiho Pharmaceutical Co., Ltd. – Drug Profiles
ABI-007 + TS-1
Abraxane
ARH-1029
Bevacizumab + S-1
CPT-11 + TS-1
Gemcitabine + TS-1
OVF
S-1 (TS-1)
S-1
S-1 + Cisplatin
S-1 + Cisplatin
S-1 + Irinotecan + Bevacizumab
S-1 + Leucovorin
S-1 + Leucovorin + Oxaliplatin + Bevacizumab
S-1 + Oxaliplatin
S-1 + Oxaliplatin + Bevacizumab
S-1 + Oxaliplatin + Leucovorin
S-1 + Sorafenib
TAC-101
TAS-102
TAS-106
TAS-108
TAS-109
TSU-68
TSU-68 + Docetaxel
TSU-68 + S-1 + Oxaliplatin
TSU-68 + TS-1 + CDDP
YP18
Taiho Pharmaceutical Co., Ltd. – Pipeline Analysis
Taiho Pharmaceutical Co., Ltd. – Pipeline Products by Therapeutic Class
Taiho Pharmaceutical Co., Ltd. – Pipeline Products by Route of Administration
Taiho Pharmaceutical Co., Ltd. – Recent Pipeline Updates
Taiho Pharmaceutical Co., Ltd. - Dormant Projects
Taiho Pharmaceutical Co., Ltd. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
IPD-1151T
TAS-109
Taiho Pharmaceutical Co., Ltd. – Company Statement
Taiho Pharmaceutical Co., Ltd. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Company's Recent Developments
Taiho Pharmaceutical Co., Ltd., Recent Developments
Jan 26, 2011: Taiho Pharmaceutical Announces Results Of Gemcitabine And TS-1 Trial On Advanced Pancreatic Cancer
Dec 17, 2010: Teysuno (S-1) receives CHMP positive opinion for approval as first-line therapy for advanced gastric cancer
Mar 14, 2011: Taiho Pharmaceutical Receives European Marketing Authorization For Teysuno (S-1) As First-Line Therapy For Advanced Gastric Cancer
Mar 14, 2011: Teysuno (S-1) receives European marketing authorization as first-line therapy for advanced gastric cancer
Jun 08, 2011: Taiho Pharmaceutical Presents Results Of GEST Clinical Study Of TS-1 In Patients With Advanced Pancreatic Cancer At ASCO
Financial Deals Landscape
Taiho Pharmaceutical Co., Ltd., Deals Summary
Taiho Pharmaceutical Co., Ltd., Pharmaceuticals & Healthcare, Deal Details
Partnerships
Taiho Pharmaceutical Enters Into Development Agreement With Nordic Group For Teysuno
MSD Enters Into Co-Marketing Agreement With Taiho Pharmaceutical For Vorinostat
Taiho Pharmaceutical Enters Into Co-Development Agreement With Ligand Pharmaceuticals
Licensing Agreements
Taiho Pharmaceutical Extends Licensing Agreement With Helsinn Healthcare
Taiho Pharmaceutical Enters Into Licensing Agreement With Pharmamar
Taiho Pharmaceutical Signs Licensing Agreement With Helsinn Healthcare
Acquisition
Toho Pharmaceutical Acquires Remaining Stake In Koyo Co
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Taiho Pharmaceutical Co., Ltd., Key Information
Taiho Pharmaceutical Co., Ltd., Key Facts
Taiho Pharmaceutical Co., Ltd. – Pipeline by Therapy Area and Indication, H2 2011
Taiho Pharmaceutical Co., Ltd. – Pipeline by Stage of Development, H2 2011
Taiho Pharmaceutical Co., Ltd. – Monotherapy Products in Pipeline, H2 2011
Taiho Pharmaceutical Co., Ltd. – Combination Treatment Modalities in Pipeline, H2 2011
Taiho Pharmaceutical Co., Ltd. – Phase III, H2 2011
Taiho Pharmaceutical Co., Ltd. - Phase II, H2 2011
Taiho Pharmaceutical Co., Ltd. - Phase I, H2 2011
Taiho Pharmaceutical Co., Ltd. – Pre-Clinical, H2 2011
Taiho Pharmaceutical Co., Ltd. - Pipeline By Therapeutic Class, H2 2011
Taiho Pharmaceutical Co., Ltd. – Pipeline By Route of Administration, H2 2011
Taiho Pharmaceutical Co., Ltd. – Recent Pipeline Updates, H2 2011
Taiho Pharmaceutical Co., Ltd. - Dormant Developmental Projects, 2010
Taiho Pharmaceutical Co., Ltd. - Discontinued Pipeline Products, 2010
Taiho Pharmaceutical Co., Ltd., Subsidiaries
Taiho Pharmaceutical Co., Ltd., Deals Summary
Taiho Pharmaceutical Enters Into Development Agreement With Nordic Group For Teysuno
MSD Enters Into Co-Marketing Agreement With Taiho Pharmaceutical For Vorinostat
Taiho Pharmaceutical Enters Into Agreement With Toray Industries
Taiho Pharmaceutical Enters Into Co-Development Agreement With Nippon Shinyaku
Makoto Life Sciences Enters Into Research Collaboration Agreement With Taiho Pharmaceutical
Yakult Honsha Enters Into Co-Promotion Agreement With Taiho Pharmaceutical
Pharmacopeia Enters Into Co-Development Agreement With Taiho Pharmaceutical
Taiho Pharmaceutical Enters Into Co-Development Agreement With Ligand Pharmaceuticals
Taiho Pharmaceutical Extends Licensing Agreement With Helsinn Healthcare
Taiho Pharmaceutical Enters Into Licensing Agreement With Pharmamar
aRigen Pharmaceuticals Enters Into Licensing Agreement With Taiho Pharmaceutical
Taiho Pharmaceutical Signs Licensing Agreement With Sanofi-Aventis
American BioScience Enters Into Licensing Agreement With Taiho Pharmaceutical
Merck Enters Into Licensing Agreement With Taiho Pharmaceutical
Taiho Pharmaceutical Signs Licensing Agreement With Helsinn Healthcare
Toho Pharmaceutical Acquires Remaining Stake In Koyo Co
LIST OF FIGURES
Taiho Pharmaceutical Co., Ltd. – Pipeline by Therapy Area and Indication, H2 2011
Taiho Pharmaceutical Co., Ltd. – Pipeline by Stage of Development, H2 2011
Taiho Pharmaceutical Co., Ltd. – Monotherapy Products in Pipeline, H2 2011
Taiho Pharmaceutical Co., Ltd. – Combination Treatment Modalities in Pipeline, H2 2011
Taiho Pharmaceutical Co., Ltd. – Pipeline By Therapeutic Class, H2 2011
Taiho Pharmaceutical Co., Ltd. – Pipeline By Route of Administration, H2 2011
Taiho Pharmaceutical Co., Ltd. Overview
Key Information
Key Facts
Taiho Pharmaceutical Co., Ltd. – Research and Development Overview
Key Therapeutic Areas
Taiho Pharmaceutical Co., Ltd. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Taiho Pharmaceutical Co., Ltd. – Pipeline Products Glance
Taiho Pharmaceutical Co., Ltd. – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Taiho Pharmaceutical Co., Ltd. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Taiho Pharmaceutical Co., Ltd. – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Taiho Pharmaceutical Co., Ltd. – Drug Profiles
ABI-007 + TS-1
Abraxane
ARH-1029
Bevacizumab + S-1
CPT-11 + TS-1
Gemcitabine + TS-1
OVF
S-1 (TS-1)
S-1
S-1 + Cisplatin
S-1 + Cisplatin
S-1 + Irinotecan + Bevacizumab
S-1 + Leucovorin
S-1 + Leucovorin + Oxaliplatin + Bevacizumab
S-1 + Oxaliplatin
S-1 + Oxaliplatin + Bevacizumab
S-1 + Oxaliplatin + Leucovorin
S-1 + Sorafenib
TAC-101
TAS-102
TAS-106
TAS-108
TAS-109
TSU-68
TSU-68 + Docetaxel
TSU-68 + S-1 + Oxaliplatin
TSU-68 + TS-1 + CDDP
YP18
Taiho Pharmaceutical Co., Ltd. – Pipeline Analysis
Taiho Pharmaceutical Co., Ltd. – Pipeline Products by Therapeutic Class
Taiho Pharmaceutical Co., Ltd. – Pipeline Products by Route of Administration
Taiho Pharmaceutical Co., Ltd. – Recent Pipeline Updates
Taiho Pharmaceutical Co., Ltd. - Dormant Projects
Taiho Pharmaceutical Co., Ltd. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
IPD-1151T
TAS-109
Taiho Pharmaceutical Co., Ltd. – Company Statement
Taiho Pharmaceutical Co., Ltd. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Company's Recent Developments
Taiho Pharmaceutical Co., Ltd., Recent Developments
Jan 26, 2011: Taiho Pharmaceutical Announces Results Of Gemcitabine And TS-1 Trial On Advanced Pancreatic Cancer
Dec 17, 2010: Teysuno (S-1) receives CHMP positive opinion for approval as first-line therapy for advanced gastric cancer
Mar 14, 2011: Taiho Pharmaceutical Receives European Marketing Authorization For Teysuno (S-1) As First-Line Therapy For Advanced Gastric Cancer
Mar 14, 2011: Teysuno (S-1) receives European marketing authorization as first-line therapy for advanced gastric cancer
Jun 08, 2011: Taiho Pharmaceutical Presents Results Of GEST Clinical Study Of TS-1 In Patients With Advanced Pancreatic Cancer At ASCO
Financial Deals Landscape
Taiho Pharmaceutical Co., Ltd., Deals Summary
Taiho Pharmaceutical Co., Ltd., Pharmaceuticals & Healthcare, Deal Details
Partnerships
Taiho Pharmaceutical Enters Into Development Agreement With Nordic Group For Teysuno
MSD Enters Into Co-Marketing Agreement With Taiho Pharmaceutical For Vorinostat
Taiho Pharmaceutical Enters Into Co-Development Agreement With Ligand Pharmaceuticals
Licensing Agreements
Taiho Pharmaceutical Extends Licensing Agreement With Helsinn Healthcare
Taiho Pharmaceutical Enters Into Licensing Agreement With Pharmamar
Taiho Pharmaceutical Signs Licensing Agreement With Helsinn Healthcare
Acquisition
Toho Pharmaceutical Acquires Remaining Stake In Koyo Co
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Taiho Pharmaceutical Co., Ltd., Key Information
Taiho Pharmaceutical Co., Ltd., Key Facts
Taiho Pharmaceutical Co., Ltd. – Pipeline by Therapy Area and Indication, H2 2011
Taiho Pharmaceutical Co., Ltd. – Pipeline by Stage of Development, H2 2011
Taiho Pharmaceutical Co., Ltd. – Monotherapy Products in Pipeline, H2 2011
Taiho Pharmaceutical Co., Ltd. – Combination Treatment Modalities in Pipeline, H2 2011
Taiho Pharmaceutical Co., Ltd. – Phase III, H2 2011
Taiho Pharmaceutical Co., Ltd. - Phase II, H2 2011
Taiho Pharmaceutical Co., Ltd. - Phase I, H2 2011
Taiho Pharmaceutical Co., Ltd. – Pre-Clinical, H2 2011
Taiho Pharmaceutical Co., Ltd. - Pipeline By Therapeutic Class, H2 2011
Taiho Pharmaceutical Co., Ltd. – Pipeline By Route of Administration, H2 2011
Taiho Pharmaceutical Co., Ltd. – Recent Pipeline Updates, H2 2011
Taiho Pharmaceutical Co., Ltd. - Dormant Developmental Projects, 2010
Taiho Pharmaceutical Co., Ltd. - Discontinued Pipeline Products, 2010
Taiho Pharmaceutical Co., Ltd., Subsidiaries
Taiho Pharmaceutical Co., Ltd., Deals Summary
Taiho Pharmaceutical Enters Into Development Agreement With Nordic Group For Teysuno
MSD Enters Into Co-Marketing Agreement With Taiho Pharmaceutical For Vorinostat
Taiho Pharmaceutical Enters Into Agreement With Toray Industries
Taiho Pharmaceutical Enters Into Co-Development Agreement With Nippon Shinyaku
Makoto Life Sciences Enters Into Research Collaboration Agreement With Taiho Pharmaceutical
Yakult Honsha Enters Into Co-Promotion Agreement With Taiho Pharmaceutical
Pharmacopeia Enters Into Co-Development Agreement With Taiho Pharmaceutical
Taiho Pharmaceutical Enters Into Co-Development Agreement With Ligand Pharmaceuticals
Taiho Pharmaceutical Extends Licensing Agreement With Helsinn Healthcare
Taiho Pharmaceutical Enters Into Licensing Agreement With Pharmamar
aRigen Pharmaceuticals Enters Into Licensing Agreement With Taiho Pharmaceutical
Taiho Pharmaceutical Signs Licensing Agreement With Sanofi-Aventis
American BioScience Enters Into Licensing Agreement With Taiho Pharmaceutical
Merck Enters Into Licensing Agreement With Taiho Pharmaceutical
Taiho Pharmaceutical Signs Licensing Agreement With Helsinn Healthcare
Toho Pharmaceutical Acquires Remaining Stake In Koyo Co
LIST OF FIGURES
Taiho Pharmaceutical Co., Ltd. – Pipeline by Therapy Area and Indication, H2 2011
Taiho Pharmaceutical Co., Ltd. – Pipeline by Stage of Development, H2 2011
Taiho Pharmaceutical Co., Ltd. – Monotherapy Products in Pipeline, H2 2011
Taiho Pharmaceutical Co., Ltd. – Combination Treatment Modalities in Pipeline, H2 2011
Taiho Pharmaceutical Co., Ltd. – Pipeline By Therapeutic Class, H2 2011
Taiho Pharmaceutical Co., Ltd. – Pipeline By Route of Administration, H2 2011
